NCT02135588

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Eastern Regional Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of intrapleural dornase alfa and tPA administered to patients with clinical failure of small-bore chest tube with persistent pleural effusions or malignancy-related loculated effusion to improve pleural drainage.

Conditions

• Loculated or Non-draining Malignant Pleural Effusions

Interventions

Type	Name	Description
DRUG	Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)

Timeline

• Start date: 2013-10-01
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2014-05-12
• Last updated: 2021-02-11

Locations

1 site across 1 country: United States